Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Enterprise Value (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Enterprise Value for 11 consecutive years, with -$64.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 45.07% to -$64.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$64.8 million, a 45.07% decrease, with the full-year FY2025 number at -$64.8 million, down 45.07% from a year prior.
  • Enterprise Value was -$64.8 million for Q4 2025 at Niagen Bioscience, down from -$64.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$13.3 million in Q3 2022 to a low of -$64.8 million in Q4 2025.
  • A 5-year average of -$34.9 million and a median of -$28.1 million in 2021 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 228.48% in 2021, then skyrocketed 59.94% in 2022.
  • Niagen Bioscience's Enterprise Value stood at -$28.2 million in 2021, then rose by 27.56% to -$20.4 million in 2022, then tumbled by 33.68% to -$27.3 million in 2023, then crashed by 63.44% to -$44.7 million in 2024, then crashed by 45.07% to -$64.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Enterprise Value are -$64.8 million (Q4 2025), -$64.3 million (Q3 2025), and -$60.5 million (Q2 2025).